Arbor Pharmaceuticals

Arbor Pharmaceuticals, operates as a specialty pharmaceutical company focusing on pediatric medicine. It engages in licensing, developing, and commercializing late-stage products for common pediatric conditions. The company's products include ZINOTIC and ZINOTIC ES, which addresses Acute Otitis Externa; NEOTIC, an otic analgesic agent for the treatment of pain and inflammation associated with Acute Otitis Media; and XYLAREX for the dietary management of Recurrent Acute Otitis Media. Its products also include Pediaderm HC Complete Kit, which is specifically developed to treat, manage, and protect the skin of children with atopic dermatitis, commonly referred to as eczema. The company markets its products specialty sales forces in the United States. Arbor Pharmaceuticals, was founded in 2006 and is based in Raleigh, North Carolina.

Arbor Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Life Science, Pharmaceutical sector. The company focuses on Biotechnology and has secured $2.4B in funding across 60 round(s). With a team of 501-1000 employees, Arbor Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Arbor Pharmaceuticals, raised $34.8M. Discover more about their projects, partnerships, and impact on our platform.